Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
Patients might gravitate toward dual agonists for a nice mix of efficacy, dosing, and side effects
Supporting these pathways helps reinforce a more balanced and sustainable approach to performance and wellness
For autoimmune patients already at risk for bone loss, this could be a clinically meaningful distinction when choosing between available GLP-1/GIP medications
The takeaway isnt that these medications should be avoided, but rather that being aware of potential cutaneous effects can help clinicians recognize medication-related skin changes quicker and manage them appropriately. For more information: Marisa Fat, BS , can be reached at [email protected].
Cell 164(6):12261232 Tomiyama EA-O, Matsuzaki KA-O, Fujita K, Shiromizu T, Narumi R, Jingushi K, Koh Y, Matsushita M, Nakano KA-O, Hayashi YA-O, Wang CA-O, Ishizuya Y, Kato TA-O, Hatano K, Kawashima AA-O, Ujike T, Uemura M, Takao T, Adachi JA-O, Tomonaga T, Nonomura NA-O (2021) Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers
